C hronic kidney disease (CKD), characterized by reduced kidney function or kidney damage for at least 3 months, 1 affects >11% of adults in the United States. 2 CKD is often associated with other chronic diseases, such as hypertension and diabetes mellitus, and is independently associated with an increased risk of cardiovascular events. 3 Furthermore, individuals with CKD have worse functional outcomes and increased mortality following cardiovascular events. 3 Thus, CKD imposes a significant disease burden, both for individuals suffering from the disease and on the healthcare system as a whole.
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smoking. The kidney and brain may be uniquely susceptible to vasculature insults given that the 2 rely on similar microvasculatures that allow for continuous high volume perfusion. Most of the studies which have identified an increased risk of stroke in patients with CKD have been retrospective cohorts data and meta-analyses. [4] [5] [6] [7] The few prospective studies of the relationship between CKD and stroke report on either specific underlying causes of CKD, such as diabetes mellitus, 8 or patients undergoing maintenance hemodialysis. 9, 10 The generalizability of these results to the larger population with CKD is uncertain. Individuals who have kidney dysfunction at the time of a stroke event have worse outcomes, 11, 12 although whether kidney dysfunction was a causative factor in the stroke mechanism is unclear. Together, these data suggest that CKD may have important implications for risk of stroke and sequelae. The Chronic Renal Insufficiency Cohort (CRIC) study was established in 2001 to prospectively follow patients with CKD from a variety of underlying causes to better understand the relationship between progressive renal disease and cardiovascular disease. 13 We hypothesized that a lower level of kidney function at baseline is associated with an increased risk of stroke, independent of other vascular risk factors. We also hypothesized that use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), which decrease urinary albumin excretion, 14 would also be associated with a reduced risk of stroke.
Methods

Study Population
The CRIC study is a prospective multicenter observational cohort of adults with moderate to advanced CKD that aims to evaluate risk factors for progression of CKD and cardiovascular disease. The study design and methods have been described in detail previously. 13 The protocol was approved at each center's institutional review board and all patients provided informed consent. Briefly, 7 clinical centers recruited adults aged 21 to 74 years who had CKD but were not on dialysis using age-based estimated glomerular filtration rate (eGFR) inclusion criteria. All patients had eGFR≥20 mL/min per 1.73 m2 at baseline; older patients were required to have the lowest baseline eGFR to avoid inclusion of subjects with age-related declines in eGFR. 13 Fifty percent of study participants had diabetes mellitus. Study recruitment was conducted by the individual clinical centers and recruited an ethnically and racially diverse study population. Subjects were followed prospectively until death or study dropout. Exclusion criteria included a diagnosis of polycystic kidney disease, prior dialysis treatment, prior organ/bone marrow transplant, immunotherapy for renal disease, or systemic vasculitis affecting the kidneys in the prior 6 months, chemotherapy/alkylating agents for systemic cancer (other than nonmelanoma skin cancer) within 2 years before study enrollment, prior diagnosis of multiple myeloma or renal carcinoma, New York Heart Association class III or IV heart failure at baseline, known diagnosis of cirrhosis or HIV/AIDs, women pregnant or breastfeeding, participants in active interventional clinical trials, or those unable or unwilling to provide informed consent. Proteinuria and albuminuria were quantified by 24-hour urine collection measured at the first study visit. Information on medication use was obtained by self-report at annual clinic visits and semiannual phone interviews.
Stroke Outcomes
Participants or their proxies were contacted every 6 months about possible cardiovascular hospitalizations, as well as outpatient cardiovascular tests or interventions. Stroke was defined as a fixed neurological deficit lasting >24 hours because of a presumed vascular cause. For all potential stroke events, reported either by the subject or their physicians, the medical records were independently reviewed and adjudicated by 2 vascular neurologists and classified as definite/ probable stroke, or no stroke. Strokes were classified as ischemic or hemorrhagic using all available information from medical records and imaging studies.
Statistical Methods
The baseline eGFR measurements, collected within 3 months of study recruitment, of participants who suffered a fatal and nonfatal stroke event during the follow-up period were compared with those who remained stroke free. Cox proportional hazard models were used to calculate hazard ratios and 95% confidence intervals for time to first stroke after study enrollment associated with baseline GFR and other markers of renal function, including 24-hour proteinuria and albuminuria.
Multivariable analysis was performed to adjust for key covariates, defined as those associated with stroke in univariate analysis at a P<0.05 level, and a priori included age, sex, and race. Each indicator of renal impairment (eGFR, proteinuria, and albuminuria) was first analyzed separately with adjustment for these covariates. Next, eGFR and albuminuria were included simultaneously. Finally, use of ACEIs or ARBs was included in the models as a potential disease-modifying therapy.
All analyses were performed using SAS software. All statistical tests were 2-sided and a result was considered significant if P<0.05.
Results
Subject Characteristics
Baseline characteristics are summarized in Table 1 . Among 3939 participants in the present CRIC analysis with a median follow-up of 6.4 years, 143 stroke events were identified in 143 patients (incidence rate: 0.62 per 100 person-years). Of the 143 stroke events, 118 were ischemic strokes, whereas the remaining 25 were intracerebral hemorrhages. Participants who suffered stroke were older, were more likely to be black, and were more likely to have a history of diabetes mellitus, prior myocardial infarction, or stroke, were active smokers, and used alcohol ( Table 1 ). The systolic blood pressure at the baseline study visit was higher in patients who subsequently had a stroke. The reported use of medications that may modify stroke risk, including aspirin, statin drugs, erythropoietin, or blockers of the renin-angiotensin system were not different between groups (Table 1 ). During the follow-up period, there were 716 deaths (18.2%) and 205 patients (2.1%) who withdrew consent or were lost to follow-up.
Kidney Function and Stroke
Baseline kidney function measures included eGFR, total protein excreted in 24 hours and albumin excretion in 24 hours ( Table 2 ). Characteristics of subject groups based on kidney function measurements are included in Tables I-III in the online-only Data Supplement.
Mean baseline eGFR measurements were lower in participants who experienced a stroke event when compared with those who did not, whereas proteinuria/albuminuria was increased in subjects with strokes ( Table 2 ). When subjects were categorized into groups based on baseline eGFR (Table 3) , there was a significantly greater risk of stroke in patients in the lowest categories of kidney function (eGFR<45 mL/min per 1.73 m2) when compared with those with the highest kidney function (eGFR>60 mL/min per 1.73 m2). In this regard, there was a dose-response relationship whereby increasing urinary protein or albumin excretion was associated with an increased risk of stroke (Table 3) .
After adjustment for age, race, sex, vascular risk factors (including diabetes mellitus, systolic blood pressure, hyperlipidemia, smoking, and alcohol use), and medications which modify urinary protein excretion (use of ACEI/ARBs) was performed. When these variables were controlled for, eGFR was no longer associated with a risk of stroke events (Table 4 ). In contrast, proteinuria >0.50 g/d or albuminuria >30 mg/d were associated with a significant increase in stroke risk after accounting for these other stroke risk factors (Table 4 ; Figure A ).
Finally, when both eGFR and albuminuria were included simultaneously in the model (Table 5) , albuminuria remained significantly associated with stroke risk, as did many known vascular risk factors, including age, black race, diabetes mellitus, systolic blood pressure, current smoking, and alcohol use.
Self-reported use of either an ACEI or an ARB did not modify the risk of stroke in individuals with albuminuria ( Figure B ).
Discussion
The CRIC study cohort provides a unique opportunity to assess the relationship between CKD and stroke risk using a variety of measures of kidney disease severity.
CKD is associated with cardiovascular disease as well as all-cause and cardiovascular-related mortality. 15 In routine clinical practice, the degree of kidney dysfunction is typically determined by measuring serum creatinine and calculating creatinine-based eGFR. However, serum creatinine is influenced by age, sex, and lean muscle mass, confounding the associations between creatinine-based eGFR measurements and outcomes. Proteinuria and albuminuria are alternative and complementary measures of renal function that measure injury to the renal filtration barrier. [16] [17] [18] Our study, performed in a large, diverse cohort of patients with CKD of a variety of underlying causes, indicate that small increases in protein and albumin excretion are associated with an increased risk of stroke. By contrast, eGFR was not associated with stroke risk after accounting for the most common vascular risk factors. This suggests that eGFR measurements alone are a poor biomarker of cerebrovascular risk in patients with CKD.
Several prior studies found that subjects with a decreased eGFR had an increased risk of stroke when compared with subjects with normal eGFR (>60 mL/min per 1.73 m2). Lee et al 6 performed a meta-analysis that found that decreased eGFR (<60 mL/min per 1.73 m2) was associated with an increased risk of stroke. Similarly, Piccini et al 19 found that eGFR<60 mL/min per 1.73 m2 increased the risk of stroke in individuals with atrial fibrillation who were not on anticoagulation therapy. These studies differ from CRIC cohort in that all subjects in the CRIC cohort had existing renal dysfunction at the time of study enrollment as determined by age-based eGFR enrollment criteria 13 (Table I in the online-only Data Supplement). In these individuals with known kidney dysfunction, proteinuria and albuminuria are more sensitive to stroke risk than eGFR measurement alone. In this regard, proteinuria was associated with an increased risk of stroke in patients with atrial fibrillation not treated with anticoagulation even after accounting for a decrease in eGFR. 20 These data support recent evidence suggesting that albuminuria may be a more sensitive biomarker for incident cardiovascular events in the general population 15, 21 and in certain disease states, such as diabetes mellitus, 22 than other markers of kidney disease, such as eGFR. Our study extends this finding to cerebrovascular disease and suggests that albuminuria can be used to predict the risk of stroke in individuals with known CKD. Prior studies have found an association of albuminuria with incident stroke in the general population, 23-26 but this is the first study to assess the association of renal biomarkers with stroke risk specifically in individuals with CKD.
Our study bolsters these earlier reports in a diverse sample of patients with CKD from a variety of pathogeneses.
In addition to the conventional vascular risk factors that are common in patients with CKD, there may be pathophysiologic mechanisms unique to CKD that predispose patients to cardiovascular and cerebrovascular events. Reduced kidney function has been associated with inflammation, thromboembolism, endothelial dysfunction, and arterial stiffness/calcification and other factors, all of which may contribute to stroke risk. [27] [28] [29] The kidney and brain both have low-resistance microvasculatures exposed to high volume, continuous perfusion. Small vessel cerebrovascular disease in the brain is mediated by endothelial dysfunction, arteriosclerosis, and blood-brain barrier disruption. Similarly, kidney dysfunction is associated with endothelial dysfunction and lipohyalinosis, both features of small vessel disease. 30 In fact, CKD has been associated with subclinical white matter abnormalities, suggesting that the 2 may share similar pathogenic mechanisms. 31 Albumin is a large protein that is normally excreted by the kidney at low levels (<30 mg/d) with 99% of filtered albumin being reabsorbed, such that <1% reaches the urine. 32 Albuminuria, therefore, reflects either an increase in the filtered albumin load or a decrease in the tubular reabsorption capacity and, in that way, has been proposed as a marker of glomerular damage. 33 Further studies have suggested that, in addition to reflecting glomerular injury, albumin secretion is also pathogenic, leading to proinflammatory and profibrotic events within the proximal tubule. 34, 35 Although the mechanisms by which albuminuria is associated with cardiovascular events are not fully understood, it has been postulated that albuminuria may reflect systemic endothelial dysfunction 36, 37 that alters inflammatory and thrombotic cascades 38,39 and contributes to atherothrombotic events, including stroke.
Albuminuria has important implications as a biomarker for stroke risk in CKD, as it is a modifiable risk factor. ACEI and ARB agents have been shown to decrease albuminuria in individuals with diabetes mellitus and hypertension 40 and decrease cardiovascular events in these patients. 2 Our data suggest that albuminuria severity may be useful to stratify patients with CKD who are at higher risk of suffering a cerebrovascular event and may aid in identifying individuals in whom therapy should be intensified. When we looked specifically at the use of ACEI/ARBs, there was a suggestion that patients with mild albuminuria (30-299 mg/d; Figure B ) might benefit from ACEI/ARB therapy, although this failed to reach statistical significance. Limitations of our study include the relatively few strokes observed in the CRIC cohort, precluding examination of differential associations of proteinuria with subtypes of stroke. The incidence of stroke in our population is similar to that reported in other studies of stroke in patients with kidney dysfunction. 23 Medical history and medication use were selfreported by participants. Medication indication, compliance, and effectiveness were not assessed. In addition, we used medication use data collected at the first study visit; changes in medication use and dose titrations were not included in the analysis. In our study, there were a small number of hemorrhagic strokes (n=25) when compared with ischemic strokes (n=118). In our analysis, we considered all strokes together. The small number of hemorrhagic stroke limited our ability to determine which factors where associated with this specific stroke type. To patients and their providers, identifying risk factors for all potential types of strokes is important and thus we chose to analyze all strokes together. As additional stroke events accrue over time, it may be possible to determine risk factors for ischemic or hemorrhagic stroke separately in patients with kidney dysfunction.
In conclusion, the CRIC cohort study supports the growing body of evidence that proteinuria is a biomarker for cardiovascular risk and extends these findings to include proteinuria and albuminuria as markers of cerebrovascular risk in subjects with CKD. These data suggest that therapies aimed at treating proteinuria/albuminuria may be worthy of further investigation for stroke prevention. In addition, the longitudinal study of the CRIC cohort will allow us to further examine how changes in albuminuria and renal function over the 10-year planned follow-up time influence stroke risk.
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